Expanding the Value Metrics in Fixed-Budget Healthcare Systems

By Staff Writer

August 20, 2024

Introduction

Traditional cost-effectiveness analysis (CEA) has long been a cornerstone in healthcare decision-making. However, its reliance on measures like quality-adjusted life-years (QALYs) has faced criticism for excluding additional value dimensions. A recent publication addresses this gap by exploring extra-welfarist (EW) methods to incorporate values beyond just health. The focus was on non-market environments, such as the British National Health Service (BNHS) and similar systems worldwide.

Limitations of Traditional CEA

CEA typically combines health-related quality of life and life expectancy into QALYs, which are then compared with associated costs. This method relies solely on individual utility measures. Similar criticisms apply to EW methods, which avoid using individual utility preferences but still focus predominantly on health. Despite its intent to include broader values, EW has not effectively incorporated gains beyond health due to a lack of clear methodologies.

Expanding Value Metrics in Healthcare

The ISPOR 2018 Task Force introduced the “Value Flower,” which catalogues potential missing value sources. These include health-related gains like productivity, real option value, reduced caregiver burden, and health equity. For example, improved health can decrease caregiver burden, measured by the rate at which burden declines as patient health improves. Table 1 provides examples of these additional values and their measurement methods. These value elements can be characterised as improvement in people’s health or depend on treatment severity.

Table 1. Examples of Health-Related Additional Values and Their Measurement

Budget Allocations and Willingness to Pay (WTP)

The ability to supply additional health comes at increasing marginal cost, influenced by available technologies and their application. Optimality is achieved when marginal cost equals WTP. For example, the BNHS budget for 2022/23 was £181.7 billion. The operative threshold for cost-effectiveness in the UK is closer to £13,000 per QALY, despite higher advertised values. This discrepancy highlights the importance of budget allocations in determining implicit WTP values.

Challenges and Solutions

Numerous conceptual problems remain in incorporating these additional values, such as double counting and assessing WTP. Double counting can be avoided through conceptualisation or statistical analysis. For instance, worker productivity and absenteeism often overlap. Professional judgement is crucial in these cases to ensure accurate valuation without redundancy.

Conclusion

When EW proponents aim to use measures other than individual utility, the only meaningful substitute becomes decision-makers’ willingness to increase healthcare budgets. This approach highlights the importance of societal values and the distribution of benefits. In fixed-budget environments, only the commitment of governments or major non-governmental organisations to fund these extra values can bring them to fruition. When we move from “health” to “welfare” in the measurement of increased healthcare value, we can develop methods with additional values that are truly expanding value metrics in healthcare.

 

 

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.